ADMET Prediction of Dual PPARα/γ Agonists for Identification of Potential Anti-diabetic Agents

  • Neha VermaEmail author
  • Usha Chouhan
Conference paper
Part of the Advances in Intelligent Systems and Computing book series (AISC, volume 748)


Since last 15 years, ex vivo experimental tools to describe ADME–Tox profiles of molecules have been exercised in initial stages of the drug development process to enhance the success percentage of discovery index and to ameliorate better candidates into drug discovery. Implementation of in silico ADMET prediction has further improved discovery support, allowing virtual screening of chemical compounds and therefore, application of ADMET property prediction at each phase of the drug development process. Recently there have been advancements in the approaches used to determine the accurateness of the prediction as well as application domain of the absorption, metabolism, distribution, excretion, and toxicity models. Developments also seen in the methods used to anticipate the physiochemical properties of leads in the initial steps of drug development. Absorption, distribution, metabolism, and excretion, ADME parameters, were calculated to investigate pharmacokinetic properties of hit compounds for the screening of new and potent anti-diabetic agents. ADME studies on a set of ligand molecules were performed by DruLiTo software. This study would permit chemists and drug-metabolism researchers to focus on compounds having maximum likelihoods of meeting the essential ADME criteria, also would add to a fall in compound attrition at late-stage.


ADMET Pharmacokinetic properties Anti-diabetic agents 



Author Neha Verma would like to acknowledge the UGC, Delhi for providing RGNFSC fellowship.


  1. 1.
    Dunstan, D.W., et al.: The rising prevalence of diabetes and impaired glucose tolerance: the Australian diabetes, obesity, and lifestyle study. Diabetes Care 25, 829–834 (2002)CrossRefGoogle Scholar
  2. 2.
    Rizvi, A.A.: Type 2 diabetes: epidemiologic trends, evolving pathogenic concepts, and recent changes in therapeutic approach. South. Med. J. 97, 1008–1027 (2004)CrossRefGoogle Scholar
  3. 3.
    Vaseem, A., Sethi, B., Kelwade, J., Ali, M.: SGLT2 inhibitor and DPP4 inhibitor co-administration in Type 2 diabetes—Are we near the “Promised Land”? Res. Rev. J. Pharmacol. Toxicol. Stud. 4, 6–11 (2016)Google Scholar
  4. 4.
    Wild, S., et al.: Global prevalence of diabetes, estimates for the year 2000 and projections for 2030. Diabetes Care 27, 1047–1053 (2004)CrossRefGoogle Scholar
  5. 5.
    International Diabetes Federation 2012, 5th edn. The Global BurdenGoogle Scholar
  6. 6.
    Carver, C.: Insulin treatment and the problem of weight gain in Type 2 diabetes. Diabetes Educ. 32, 910–917 (2006)CrossRefGoogle Scholar
  7. 7.
    Cavaghan, M.K., et al.: Interactions between insulin resistance and insulin secretion in the development of glucose intolerance. J. Clin. Investig. 106, 329–333 (2000)CrossRefGoogle Scholar
  8. 8.
    UK Prospective Diabetes Study Group: Overview of 6 years’ therapy of Type II diabetes: a progressive disease. Diabetes 44, 1249–1258 (1995)Google Scholar
  9. 9.
    Issemann, I., Green, S.: Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature 347, 645–650 (1990)CrossRefGoogle Scholar
  10. 10.
    Naidenow, J., Hrgovic, I., Doll, M., Jahn, T.H., Lang, V., Kleemann, J., Kippenberger, S., Kaufmann, R., Zoller, N., Meissner, M.: Peroxisome proliferator-activated receptor (PPAR) α and δ activators induce ICAM-1 expression in quiescent non stimulated endothelial cells. J. Inflamm. 13, 27 (2016)CrossRefGoogle Scholar
  11. 11.
    Grygiel-Górniak, B.: Peroxisome proliferator-activated receptors and their ligands: nutritional and clinical implications–a review. Nutr. J. 13, 17 (2014)CrossRefGoogle Scholar
  12. 12.
    Hansen, M.K., Connolly, T.M.: Nuclear receptors as drug targets in obesity, dyslipidemia and atherosclerosis. Curr. Opin. Investig. Drugs 9, 247–255 (2008)Google Scholar
  13. 13.
    Mansour, M.: The roles of peroxisome proliferator-activated receptors in the metabolic syndrome. Prog. Mol. Biol. Transl. Sci. 121, 217–266 (2014)CrossRefGoogle Scholar
  14. 14.
    Torra, I.P., Chinetti, G., Duval, C., Fruchart, J.C., Staels, B.: Peroxisome proliferator-activated receptors: from transcriptional control to clinical practice. Curr. Opin. Lipidol. 12, 245–254 (2001)CrossRefGoogle Scholar
  15. 15.
    Duan, S.Z., Usher, M.G., Mortensen, R.M.: PPARs: the vasculature, inflammation and hypertension. Curr. Opin. Nephrol. Hypertens. 18, 128–133 (2009)CrossRefGoogle Scholar
  16. 16.
    Gross, B., Staels, B.: PPAR agonists: multimodal drugs for the treatment of Type-2 diabetes. Best Pract. Res. Clin. Endocrinol. Metab. 21, 687–710 (2008)CrossRefGoogle Scholar
  17. 17.
    Monsalve, F.A., Pyarasani, R.D., Delgado-Lopez, F., Moore-Carrasco, R.: Peroxisome proliferator-activated receptor targets for the treatment of metabolic diseases. Mediat. Inflamm. 549627 (2013)Google Scholar
  18. 18.
    Lyon, C.J., Law, R.E., Hsueh, W.A.: Minireview: adiposity, inflammation, and atherogenesis. Endocrinology 144, 2195–2200 (2003)CrossRefGoogle Scholar
  19. 19.
    Lohray, B.B., Lohray, V.B., Bajji, A.C., Kalchar, S., Poondra, R.R., Padakanti, S., Chakrabarti, R., Vikramadithyan, R.K., Misra, P., Juluri, S., Mamidi, N.V.S.R., Rajagopalan, R.: (−)3-[4-[2-(Phenoxazin-10-yl)ethoxy]phenyl]-2-ethoxypropanoic Acid [(−)DRF 2725]: A dual PPAR agonist with potent antihyperglycemic and lipid modulating activity. J. Med. Chem. 44, 2675–2678 (2001)CrossRefGoogle Scholar
  20. 20.
    Duran-Sandoval, D., Thomas, A.C., Bailleul, B., Fruchart, J.C., Staels, B.: Pharmacology of PPARα, PPARγ and dual PPARα/γ agonists in clinical development. Medicine/Sciences 19, 819–825 (2003)CrossRefGoogle Scholar
  21. 21.
    Henke, B.R.: Peroxisome proliferator-activated receptor α/γ dual agonists for the treatment of Type 2 diabetes. J. Med. Chem. 47, 4118–4127 (2004)CrossRefGoogle Scholar
  22. 22.
    Forman, B.M., Chen, J., Evans, R.M.: Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors alpha and delta. Proc. Natl. Acad. Sci. U.S.A. 94, 4312–4317 (1997)CrossRefGoogle Scholar
  23. 23.
    Caijo, F., et al.: Synthesis of new carbo- and heterocyclic analogues of 8-HETE and evaluation of their activity towards the PPARs. Bioorganic Med. Chem. Lett. 15, 4421–4426 (2005)CrossRefGoogle Scholar
  24. 24.

Copyright information

© Springer Nature Singapore Pte Ltd. 2019

Authors and Affiliations

  1. 1.Department of Mathematics, Bioinformatics and Computer ApplicationsMANITBhopalIndia

Personalised recommendations